-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Principal investigator Sara A. Hurvitz, MD, said results with the gedatolisib combinations show they could be the new standard of care in HR+/HER2- advanced breast cancer. | Image: Fred Hutch

In VIKTORIA-1, Gedatolisib Combos Cut Risk of Progression by Half vs Alpelisib in PIK3CA-Mutant Advanced Breast Cancer

June 19th 2026

Iain MacPherson, MD, PhD, FRCP, professor of breast oncology at the University of Glasgow, discusses results from the OPTIMA trial. | Image: BreastCancer.org

OPTIMA: Prosigna Test Finds Which Patients With Breast Cancer Can Skip Chemotherapy

ByElla Hohmann, MS

June 19th 2026

Coral Omene, MD, PhD | Image Credit: Rutgers Cancer Institute

Access and Disparity Questions Around Rilvegostomig+T-DXd: Coral Omene, MD, PhD

ByElla Hohmann, MS,Coral Omene, MD, PhD

June 15th 2026

Nancy Lin, MD | Image Credit: Dana Farber Cancer Institute

Validation, Access, and Payer Consideration for AI Diagnostics in Breast Cancer: Nancy Lin, MD

ByElla Hohmann, MS,Nancy Lin, MD

June 12th 2026

Coral Omene, MD, PhD | Image Credit: Rutgers Cancer Institute

The Combination Changing the Neoadjuvant Calculus in Breast Cancer: Coral Omene, MD, PhD

ByElla Hohmann, MS,Coral Omene, MD, PhD

June 12th 2026

Trending on AJMC

Patient Portal Messages Outpace Office Visits

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD

FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies